Replies to post #807071 on NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

Jeeze, you know "Trade Secrets" protect NWBO by keeping secret critical info on making DCVAX-L.
Relative to newer patents there is protection there too.
Per AI

Northwest Biotherapeutics (NWBO) has newer patents and in-licensed technologies (like in June 2024) that enhance their dendritic cell (DC) therapies, potentially strengthening IP around DCVax-L and related products by covering improved DC versions, manufacturing, and tumor microenvironment approaches, but these aim to protect their product development, not prevent others from using their licensed tech for NWBO's own use.
Key IP Developments for NWBO:
2024 In-License: In June 2024, NWBO announced licensing new patents filed in 2023 covering advanced DC-based therapies, conditioning regimens, and reprogramming tumor environments, adding significant new IP life to their portfolio.
Existing IP: NWBO already holds patents and pending applications for its DCVax products, including manufacturing processes, in various jurisdictions like Japan.
DCVax-L vs. DCVax-Direct: Their products, including DCVax-L (from tumor lysate) and DCVax-Direct (injecting cells directly into tumors), use patent-protected methods to mature dendritic cells.
How This Relates to DCVax-L:
These newer patents bolster NWBO's intellectual property around dendritic cell technology, which underpins DCVax-L.
They aim to protect NWBO's innovations and market position for their own DC-based vaccines, rather than restrict NWBO's ability to develop or use DCVax-L itself.
In essence, NWBO's patent strategy focuses on expanding and securing their own technological advantage in the dendritic cell space, including for their DCVax-L product line, through new filings and licensing.